Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127010
Status:
COMPLETED
Last Update Posted:
2016-09-26
First Post:
2005-08-04
Brief Title:
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles Mumps Rubella and Chickenpox Diseases
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Blinded Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline GSK Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life
Detailed Description:
This study included an active control group who received the licensed Priorix measles mumps rubella MMR vaccine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None